About Diasure Bio
Diasure Bio is a company based in Seoul (South Korea) founded in 2022. Diasure Bio has raised $71.47 thousand across 1 funding round from investors including InfoBank. Diasure Bio offers products and services including Electrochemical BioSensor and 3D Printing Technology. Diasure Bio operates in a competitive market with competitors including Access Bio, SD Biosensor, Lumos Diagnostics, Fluxergy and Module Innovations, among others.
- Headquarter Seoul, South Korea
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website diasurebio.com
- Legal Name (주)다이아슈어바이오
- Date of Incorporation 10 Aug, 1977
- Jurisdiction Maharashtra, India
- Total Equity Funding$71.47K (USD)
in 1 rounds
- Latest Funding Round$71.47K (USD), Seed
Nov 2024
- Investors
Associated legal entities of Diasure Bio
Diasure Bio operates through , (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| , CIN U99999MH1977PLC010754 | Active | 10 Aug 1977 | Nanded, Maharashtra | – | – | – | View details |
Products & Services of Diasure Bio
Diasure Bio offers a comprehensive portfolio of products and services, including Electrochemical BioSensor and 3D Printing Technology.
Device for detecting biological signals in early disease diagnosis.
System for creating medical prototypes using advanced printing methods.
Funding Insights of Diasure Bio
Diasure Bio has successfully raised a total of $71.47K through 1 strategic funding round. The most recent funding activity was a Seed round of $71.47 thousand completed in November 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $71,475
- Total Rounds 1
- Last Round Seed β $71,475
- First Round $71,475
(Nov 2024)
- Investors Count 1
All 1 funding rounds of Diasure Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2024 | $71,475 | Seed | β | β |
1 investors in total: 1 institutional.
Investors in Diasure Bio
Diasure Bio has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include InfoBank.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
IT service suite solutions are provided for various business needs. | 1995 | infobank.net | Seongnam-si, South Korea |
Investor details for Diasure Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Diasure Bio
1 people are tracked at Diasure Bio (1 in leadership).
| Name | Role | Group |
|---|---|---|
Seunghwa Lee | CEO | Leadership |
Complete people profiles for Diasure Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Diasure Bio
2 dated milestones of Diasure Bio across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Diasure Bio is founded.
- Funding First funding round of $71K.
Competitors of Diasure Bio
Diasure Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Access Bio, SD Biosensor, Lumos Diagnostics, Fluxergy and Module Innovations, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| accessbio.net | 2001 | Somerset, United States | $22M | 52 | In vitro rapid diagnostic tests, biosensor, and molecular diagnostic products for diagnosis of infectious diseases. | |
| sdbiosensor.com | 2001 | Suwon-si, South Korea | – | – | Biosensors for point-of-care diagnostics are developed by SD Biosensor. | |
| lumosdiagnostics.com | 2017 | Carlsbad, United States | $40M | – | Diversified diagnostic assays and readers are developed for point-of-care use. | |
| fluxergy.com | 2011 | Irvine, United States | – | 74 | Provides diagnostic devices and software for clinical and veterinary point-of-care testing. | |
| moduleinnovations.com | 2014 | Pune, India | $799,890 | – | Diagnostics strip for bacterial detection | |
| dxgenco.com | 2016 | – | – | – | Point-of-care diagnostic products for diabetes and tuberculosis are provided. | |
| shanxmedtech.com | 2019 | Eindhoven, Netherlands | – | – | In vitro diagnostic platforms for antibiotic testing are provided. | |
| alantissciencesindia.com | 2020 | Manipal, India | – | – | Molecular biology and microbiology research services are provided for diagnostics. | |
| novo-dx.com | 2022 | Boca Raton, United States | $1.2M | – | Point-of-care diagnostic tests are developed for in-home and clinical use. |
Detailed competitors of Diasure Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to Diasure Bio
10 companies that operate in the same segment as Diasure Bio (Infectious Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Clinical diagnostics and drug discovery for immune diseases are provided. | 2009 | Seattle, Washington, United States | USD 419.15 M | USD 276.98 M | 619 | |
Vaccines for infectious diseases are developed using cell-free protein synthesis. | 2013 | Foster City, California, United States | USD 347 M | – | 414 | |
Portable PCR diagnostics for infectious diseases are developed. | 2010 | San Jose, California, United States | USD 386.33 M | – | – | |
Developing glucan synthase inhibitors for the treatment of fungal infections. | 1999 | Jersey City, New Jersey, United States | USD 62.65 M | USD 20.6 M | 28 | |
Sherlock Biosciences is focused on molecular diagnostics development. | 2019 | Watertown, United States | USD 111 M | – | 33 | |
Provider of diagnostic solutions for systemic infections | 2016 | San Francisco, California, United States | USD 191.47 M | – | 54 | |
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Diasure Bio
Diasure Bio was founded in 2022 and raised its 1st funding round 2 years after it was founded.
Diasure Bio is headquartered in Seoul, South Korea.
Seunghwa Lee is the current CEO of Diasure Bio.
Diasure Bio is a funded company, having raised a total of $71.47K across 1 funding round to date. The company's 1st funding round was a Seed of $71.47K, raised on Nov 2024.
Diasure Bio was founded in 2022 and is based in Seoul, South Korea. Operations focus on the diagnostics sector, where point-of-care testing platforms are provided. Analysis methods and products for diagnosing infectious and genetic diseases are developed using 3D printing technology. The company targets rapid antigen testing solutions to support medical diagnostics in various settings.
Diasure Bio's top competitors include Access Bio, SD Biosensor and Lumos Diagnostics.
Diasure Bio offers Electrochemical BioSensor and 3D Printing Technology.
Diasure Bio has 1 investor. Key investors include InfoBank.
Diasure Bio operates through ,.